Показано 0 из 0
Дата |
---|
26.06.2024 |
25.06.2024 |
20.06.2024 |
14.06.2024 |
13.06.2024 |
12.06.2024 |
11.06.2024 |
10.06.2024 |
28.05.2024 |
21.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.035
|
0.08
|
0.0792
|
0.069
|
0.0792
|
0.069
|
|
|
209.04
|
4.00
|
0.035
|
0.08
|
0.0673
|
0.0673
|
0.0679
|
0.0679
|
|
|
65.95
|
5.00
|
0.035
|
0.051
|
0.051
|
0.051
|
0.051
|
0.051
|
|
|
99.81
|
1.00
|
0.035
|
0.08
|
0.0601
|
0.036
|
0.0601
|
0.0363
|
|
|
431.20
|
85.00
|
0.035
|
0.08
|
0.04
|
0.04
|
0.0419
|
0.04
|
|
|
137.04
|
41.00
|
0.035
|
0.08
|
0.0493
|
0.0461
|
0.061
|
0.0461
|
|
|
201.40
|
85.00
|
0.035
|
0.08
|
0.052
|
0.036101
|
0.052
|
0.036101
|
|
|
144.07
|
44.00
|
0.035
|
0.08
|
0.0363
|
0.0362
|
0.0363
|
0.0362
|
|
|
28.98
|
7.00
|
0.035
|
0.07
|
0.066
|
0.066
|
0.0679
|
0.0679
|
|
|
80.56
|
6.00
|
0.035
|
0.0666
|
0.054
|
0.053899
|
0.054
|
0.054
|
|
|
922.73
|
11.00
|
Estrella Immunopharma, Inc. operates as a preclinical-stage biopharmaceutical company. The Company focuses on developing CD19 and CD22-targeted T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella Immunopharma serves customers worldwide.